Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Inovio Pharmaceuticals
Thumbnail
February 07, 2023

Bristol exit clips Dragonfly’s wings

Thumbnail
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Article image
Vantage logo
November 17, 2021

Atea’s woes grow while other Covid readouts approach

Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.

Article image
Vantage logo
September 03, 2021

No let-up in Covid-19 vaccine trials

A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.

Article image
Vantage logo
May 19, 2021

Glaxo’s Covid-19 effort progresses, this time thanks to Medicago

Article image
Vantage logo
May 11, 2021

Covid-19 vaccine leaders make hay while Novavax flounders

Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.

Article image
Vantage logo
April 22, 2021

Valneva joins the phase 3 Covid-19 vaccine club

Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.

Article image
Vantage logo
March 02, 2021

Inovio’s reinvention falls flat

The company’s claims of a win with its cervical precancer therapy candidate look questionable.

Article image
Vantage logo
February 01, 2021

Covid-19 vaccine pipeline builds as Clover and Dynavax push on

Article image
Vantage logo
December 31, 2020

Clinical developments over the Christmas period 2020

Trial results in Covid-19 and cancer emerge, but little promise is seen.

Article image
Vantage logo
October 22, 2020

The growing exposure to novel Covid-19 treatments

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up